Urothelial cancer is one of the most common malignancies of the urinary tract, arising from the urothelium—the specialized epithelial lining of the bladder, ureters, renal pelvis, and urethra. Accurate diagnosis and precise ICD-10 coding are essential for proper clinical management, insurance reimbursement, and population-level cancer surveillance.
Key Takeaways
- Urothelial cancer originates in the urothelial lining and most commonly affects the bladder.
- The ICD-10-CM system classifies urothelial carcinoma by anatomical location and histological subtype.
- Hematuria is the hallmark symptom and frequently triggers diagnostic workup and ICD-10 coding.
- Selecting the correct urothelial bladder cancer ICD-10 billing code requires specificity regarding tumor stage and site.
- Coders must document laterality, behavior (malignant vs. in situ), and anatomical sub-site to avoid claim denials.
What Is Urothelial Cancer and How Is It Classified?
Urothelial carcinoma (UC) refers to a malignancy that develops from urothelial cells lining the inner surface of the urinary tract. These cells are uniquely capable of stretching and contracting, making them susceptible to prolonged exposure to carcinogens excreted in urine. The bladder is the most frequently affected organ, accounting for approximately 90–95% of all urothelial malignancies, according to the American Cancer Society. Globally, bladder cancer—most of which is urothelial in origin—ranks as the tenth most common cancer, with an estimated 573,000 new cases diagnosed worldwide each year, per World Health Organization data.
Clinically, urothelial cancer is stratified by grade and stage. Low-grade tumors tend to recur but rarely invade surrounding muscle tissue, while high-grade tumors are more aggressive and carry a significant risk of muscle invasion and distant metastasis. Stage is defined using the TNM (tumor, node, metastasis) system, ranging from non-muscle-invasive disease (Ta, T1) to deeply invasive or metastatic cancer (T2–T4, N+, M+). This staging distinction is critical not only for treatment planning but also for selecting the correct ICD-10 diagnosis code, as different stages and behaviors map to distinct code categories.
Beyond the bladder, urothelial cancer also arises in the upper urinary tract—specifically the renal pelvis and ureter—which together account for roughly 5–10% of all urothelial malignancies. Urethral involvement is rare but documented. The ICD-10-CM classification system accounts for these varied anatomical presentations, enabling coders and clinicians to capture location-specific data that informs both patient care and healthcare analytics.
Urothelial Cancer ICD-10 Codes by Carcinoma Type and Location
The ICD-10 code for urothelial carcinoma is drawn from the ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) coding system maintained by the Centers for Medicare and Medicaid Services (CMS) and the CDC. Codes are organized primarily under Chapter 2 (Neoplasms), with the specific code depending on the tumor’s anatomical location, behavior (malignant, in situ, benign, uncertain), and histological type. Understanding the full range of urothelial carcinoma types and ICD-10 codes ensures both clinical accuracy and compliant billing.
For bladder-specific urothelial malignancies, the primary code category is C67, which is further subdivided by sub-site within the bladder. For example, C67.0 corresponds to the trigone of the bladder, C67.1 to the dome, and C67.9 to an unspecified part of the bladder. In situ urothelial carcinoma of the bladder is classified under D09.0. Upper tract urothelial cancers are coded separately: renal pelvis malignancies fall under C65 (with laterality specified as C65.1 for the right and C65.2 for the left), while ureteral cancers are assigned to C66 using the same laterality convention. Urethral urothelial carcinoma is captured under C68.0.
| Anatomical Location | ICD-10-CM Code | Notes |
|---|---|---|
| Bladder (unspecified site) | C67.9 | Use more specific sub-site codes when documented |
| Bladder trigone | C67.0 | Common site for transitional cell tumors |
| Bladder, dome | C67.1 | — |
| Carcinoma in situ, bladder | D09.0 | Non-invasive high-grade lesion |
| Renal pelvis (right / left) | C65.1 / C65.2 | Laterality required |
| Ureter (right / left) | C66.1 / C66.2 | Laterality required |
| Urethra | C68.0 | Rare urothelial site |
The urothelial cancer ICD-10 classification also accommodates secondary (metastatic) lesions. When urothelial cancer spreads to lymph nodes or distant organs, secondary malignancy codes from the C77–C79 range are assigned in addition to the primary site code. Accurate dual coding of primary and secondary sites is required for complete encounter documentation under ICD-10-CM guidelines.
Urothelial Cancer Symptoms That Inform ICD-10 Diagnosis Coding
Recognizing the clinical presentation of urothelial cancer is a prerequisite for selecting the correct urothelial cancer diagnosis code ICD-10. ICD-10-CM guidelines instruct coders to assign a confirmed diagnosis code only when the treating provider has established the diagnosis. When a definitive diagnosis has not yet been confirmed, symptom codes are used as the primary code until pathological confirmation is available.
The most characteristic symptom of urothelial cancer is hematuria—blood in the urine—which may be visible to the naked eye (gross hematuria, R31.0) or detectable only on urinalysis (microscopic hematuria, R31.2). According to the National Cancer Institute, hematuria is present in approximately 85% of bladder cancer cases at diagnosis. Other presenting symptoms include urinary urgency, increased urinary frequency, dysuria (painful urination), and pelvic discomfort. In advanced or metastatic disease, patients may experience flank pain, lower extremity edema from lymphatic obstruction, or constitutional symptoms such as unintentional weight loss and fatigue.
When urothelial cancer symptoms and ICD-10 coding intersect during the diagnostic workup phase, coders rely on symptom codes to capture the clinical picture accurately. For instance, a patient presenting with gross hematuria undergoing cystoscopy would initially be coded with R31.0 until biopsy results confirm malignancy. Once confirmed, the appropriate C67.x or equivalent code replaces or supplements the symptom code. This sequencing distinction matters enormously for claims processing and quality reporting.
- Gross hematuria — visible blood in urine; ICD-10 code R31.0
- Microscopic hematuria — detected on dipstick or microscopy; ICD-10 code R31.2
- Dysuria — painful or burning urination; ICD-10 code R30.0
- Urinary frequency — abnormally frequent urination; ICD-10 code R35.0
- Flank or pelvic pain — may indicate upper tract involvement or local invasion; ICD-10 code R10.2x
Providers should document symptom specifics thoroughly in clinical notes. Detailed documentation enables coders to assign the most granular codes available, reducing the likelihood of payer queries or claim denials related to medical necessity.
Applying the Correct ICD-10 Billing Code for Urothelial Bladder Cancer
The urothelial bladder cancer ICD-10 billing code must reflect the highest level of specificity available in the clinical documentation. Under ICD-10-CM Official Guidelines for Coding and Reporting, coders are instructed to select the most specific code that accurately describes the patient’s condition. For bladder urothelial carcinoma, this means specifying the anatomical sub-site within the bladder whenever the provider has documented it, rather than defaulting to C67.9 (unspecified).
Correct code assignment also requires attention to the distinction between primary and secondary malignancy, the behavior of the neoplasm (malignant vs. in situ), and any relevant comorbidities that affect treatment decisions. In cases where a patient is receiving active chemotherapy or immunotherapy for urothelial cancer, the encounter should include the appropriate active malignancy code along with a Z-code for the type of encounter (e.g., Z51.11 for encounter for antineoplastic chemotherapy). For surgical encounters such as transurethral resection of bladder tumor (TURBT), the primary diagnosis code should reflect the confirmed urothelial malignancy, supported by operative and pathology reports.
Payers, including Medicare and commercial insurers, cross-reference diagnosis codes against procedure codes and clinical documentation to validate medical necessity. Mismatched or non-specific codes can trigger audits, claim denials, or recoupment requests. For this reason, urology practices and oncology billing teams benefit from regular coder education on urothelial cancer coding updates, particularly when CMS releases annual ICD-10-CM addenda that may introduce new codes or revise existing ones. Staying current with these updates ensures that the urothelial cancer ICD-10 code assigned at each encounter is both accurate and compliant with the applicable coding year guidelines.
Finally, when documenting follow-up visits for patients in remission or under active surveillance after treatment, coders should use the appropriate personal history code—Z85.51 for personal history of malignant neoplasm of bladder—rather than an active malignancy code. This distinction affects risk stratification, quality metrics, and downstream analytics used by health systems and payers to track cancer care outcomes.
Frequently Asked Questions
Which ICD-10-CM code is used for transitional cell carcinoma of the bladder?
Transitional cell carcinoma—the older term for urothelial carcinoma—of the bladder is classified under category C67 in ICD-10-CM. The specific sub-code depends on the tumor’s location within the bladder. C67.9 is assigned when the sub-site is not documented, while codes such as C67.0 (trigone) or C67.1 (dome) are used when the provider has identified the precise location. In situ disease is captured under D09.0 rather than a C67 code.
Can symptom codes be used for urothelial cancer before a diagnosis is confirmed?
Yes. ICD-10-CM guidelines permit symptom codes—such as R31.0 for gross hematuria or R30.0 for dysuria—as the primary diagnosis code during the diagnostic workup phase when a confirmed malignancy has not yet been established. Once pathology confirms urothelial cancer, the appropriate malignancy code from category C67, C65, C66, or C68 should be used and the symptom code is generally no longer reported separately, unless it represents a distinct additional condition.
Are separate ICD-10 codes required for upper tract urothelial carcinoma?
Yes. Upper tract urothelial carcinoma affecting the renal pelvis is coded under C65, and ureteral involvement is coded under C66. Both categories require laterality specification—right (C65.1, C66.1), left (C65.2, C66.2), or bilateral (C65.8, C66.8 where applicable)—distinct from bladder codes under C67. These anatomical distinctions are not interchangeable in ICD-10-CM and must align with provider documentation to ensure accurate billing and epidemiological reporting.
